• Policy
• National lot release for Moderna's bivalent COVID-19 vaccine
• by Lee, Hye-Kyung Oct 13, 2022 06:08am

• Policy
• The loss of health insurance is close to 200 billion won
• by Lee, Jeong-Hwan Oct 13, 2022 06:08am

• Company
• The third PD-1 immuno-cancer drug is about to enter Korea
• by Eo, Yun-Ho Oct 12, 2022 05:50am

• Policy
• 99 items were granted generic exclusivity, none reimbursed
• by Lee, Tak-Sun Oct 12, 2022 05:50am

• Policy
• Ponesimod's Domestic Item License
• by Lee, Hye-Kyung Oct 12, 2022 05:50am

• Policy
• Alvogen’s Alymsys reimbursed...compete with Avastin similar
• by Lee, Tak-Sun Oct 12, 2022 05:50am

• Company
• Reimb for Ilaris unclear... benefits 13 patients in Korea
• by Eo, Yun-Ho Oct 11, 2022 05:51am

• Company
• Hemlibra, emerged as an issue of the National Audit Office
• by Nho, Byung Chul Oct 11, 2022 05:50am

• Company
• Will the premium vaccine market rebound?
• by Kim, Jin-Gu Oct 11, 2022 05:50am

• Company
• Emergency Contraception (EC) monopolized by Hyundai
• by Oct 11, 2022 05:50am